Biblio

Author [ Title(Asc)] Type Year
Filters: Author is Matsuoka, Ken-Ichi  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
S
Saeki K, Fujiwara H, Seike K, Kuroi T, Nishimori H, Tanaka T, Matsuoka K-I, Fujii N, Maeda Y. Sigle Agent of Posttransplant Cyclophosphamide Without Calcineurin Inhibitor Controls Severity of Experimental Chronic GVHD. Acta Med Okayama. 2024;78(2):123-134.
Konuma T, Itonaga H, Ishiyama K, Doki N, Uchida N, Sawa M, Katayama Y, Tanaka M, Ueda Y, Onizuka M, et al. Should a matched sibling donor still be considered the primary option for allogeneic hematopoietic cell transplantation in patients over 50 years of age with myelodysplastic syndrome?. Bone Marrow Transplant. 2023.
R
Saburi M, Oshima K, Takano K, Inoue Y, Harada K, Uchida N, Fukuda T, Doki N, Ikegame K, Matsuo Y, et al. Risk factors and outcome of Stenotrophomonas maltophilia infection after allogeneic hematopoietic stem cell transplantation: JSTCT, Transplant Complications Working Group. Ann Hematol. 2023.
Yamamoto M, Sato M, Onishi Y, Sasahara Y, Sano H, Masuko M, Nakamae H, Matsuoka K-I, Ara T, Washio K, et al. The Registry Data Analysis of HSCT on Systemic Chronic Active EBV Infection Patients in Japan. Am J Hematol. 2022.
P
Itonaga H, Miyazaki Y, Fujioka M, Aoki J, Doki N, Nishida T, Fukuda T, Uchida N, Ueda Y, Uehara Y, et al. Prognostic impact of the conditioning intensity on outcomes after allogeneic transplantation for MDS with low blasts: a nationwide retrospective study by the adult MDS working group of the Japan Society for Transplantation and Cellular Therapy. Bone Marrow Transplant. 2024.
Shibata S, Arai Y, Kondo T, Mizuno S, Yamasaki S, Akasaka T, Doki N, Ota S, Maruyama Y, Matsuoka K-I, et al. Prognostic factors in haploidentical transplantation with post-transplant cyclophosphamide for acute myeloid leukemia. Cytotherapy. 2024.
Kitamura W, Fujii N, Nawa Y, Fujishita K, Sugiura H, Yoshioka T, Fujiwara Y, Usui Y, Fujii K, Fujiwara H, et al. Possible prognostic impact of WT1 mRNA expression at day + 30 after haploidentical peripheral blood stem cell transplantation with posttransplant cyclophosphamide for patients with myeloid neoplasm: a multicenter study from the Okayama Hematological S. Int J Hematol. 2022.
Nakaya Y, Nakamae H, Nishikubo M, Kondo E, Fukuda T, Hiramoto N, Mori Y, Nagafuji K, Eto T, Onishi Y, et al. Peripheral blood stem cell transplantation using HLA-haploidentical donor with post-transplant cyclophosphamide versus HLA-matched sibling donor for lymphoma. Bone Marrow Transplant. 2024.
O
Itonaga H, Kida M, Hamamura A, Uchida N, Ozawa Y, Fukuda T, Ueda Y, Kataoka K, Katayama Y, Ota S, et al. Outcome of therapy-related myelodysplastic syndrome and oligoblastic acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: A propensity score matched analysis. Hematol Oncol. 2022.
Kurosawa S, Shimomura Y, Tachibana T, Ishiyama K, Ota S, Kobayashi T, Uchida N, Fukushima K, Ashida T, Matsuoka K-I, et al. Outcome of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic/myeloproliferative neoplasms-unclassifiable: a retrospective nationwide study of the Japan Society for Hematopoietic Cell Transplantation: Allo-HSCT for patient. Biol Blood Marrow Transplant. 2020.
Kida M, Usuki K, Uchida N, Fukuda T, Katayama Y, Kondo T, Eto T, Matsuoka K-I, Matsuhashi Y, Ota S, et al. Outcome and Risk Factors for Therapy-Related Myeloid Neoplasms Treated with Allogeneic Stem Cell Transplantation in Japan. Biol Blood Marrow Transplant. 2020.
N
Teshima T, Boelens JJan, Matsuoka K-I. Novel insights into GVHD and immune reconstitution after allogeneic hematopoietic cell transplantation. Blood Cell Ther. 2023;6(2):42-48.
M
Komura A, Meguri Y, Matsubara C, Fujiwara H, Yukawa R, Hayashino K, Nakamura M, Yoshida C, Yamamoto K, Matsuoka K-I, et al. [Myelodysplastic syndrome with der (1;7)(q10;p10) complicated with eosinophilia and organizing pneumonia]. Rinsho Ketsueki. 2023;64(7):619-625.
Kako S, Yamazaki H, Ohashi K, Ozawa Y, Ota S, Kanda Y, Maeda T, Kato J, Ishiyama K, Matsuoka K-I, et al. Mixed chimerism and secondary graft failure in allogeneic hematopoietic stem cell transplantation for aplastic anemia. Biol Blood Marrow Transplant. 2019.
L
Fuji S, Sugita J, Najima Y, Konishi T, Tanaka T, Ohigashi H, Eto T, Nagafuji K, Hiramoto N, Matsuoka K-I, et al. Low- versus standard-dose post-transplant cyclophosphamide as GVHD prophylaxis for haploidentical transplantation. Br J Haematol. 2023.
Fujimoto A, Hiramoto N, Yamasaki S, Inamoto Y, Ogata M, Sugio Y, Fukuda T, Uchida N, Ikegame K, Matsuoka K-I, et al. Low incidence of post-transplant lymphoproliferative disorder after allogeneic stem cell transplantation in patients with lymphoma treated with rituximab. Hematol Oncol. 2020.
I
Murase K, Kim HT, Bascug ORGregory, Kawano Y, Ryan J, Matsuoka K-I, Davids MS, Koreth J, Ho VT, Cutler C, et al. Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. Haematologica. 2014.
Hayashi H, Iwasaki M, Nakasone H, Tanoshima R, Shimabukuro M, Takeda W, Nishida T, Kako S, Fujiwara S-I, Katayama Y, et al. Impact of stem cell selection between bone marrow and peripheral blood stem cells for unrelated hematopoietic stem cell transplantation for hematologic malignancies: on behalf of the Donor/Source Working Group of the Japanese Society for Transplantation a. Cytotherapy. 2023.
Konishi T, Matsuda K, Itonaga H, Doki N, Nishida T, Matsuoka K-I, Ikeda T, Kanda Y, Fukuda T, Kanda J, et al. Impact of Early Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation on Relapse in Patients with Myelodysplastic Syndrome: A Nationwide Retrospective Study from Adult Myelodysplastic Syndrome Working Group of the JSTCT. Transplant Cell Ther. 2024.
Yamamoto R, Hiramoto N, Fujimoto A, Yamazaki H, Mori T, Uchida N, Doki N, Kato J, Nishikubo M, Kako S, et al. Impact of antithymocyte globulin usage and risk stratification for posttransplant lymphoproliferative disorders in aplastic anemia patients after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2024.
Tamaki M, Akahoshi Y, Ashizawa M, Misaki Y, Koi S, Kim S-W, Ozawa Y, Fujiwara S-I, Kako S, Matsuoka K-I, et al. Impact of anti-thymocyte globulin on survival outcomes in female-to-male allogeneic hematopoietic stem cell transplantation. Sci Rep. 2023;13(1):7166.
H
Nakaya Y, Koh H, Konuma T, Shimomura Y, Ishiyama K, Itonaga H, Hino M, Doki N, Nishida T, Ohigashi H, et al. HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide versus HLA-Matched Unrelated Donor Transplantation for Myelodysplastic Syndrome. Transplant Cell Ther. 2023.
Fukunaga K, Ikegame K, Nakamae H, Doki N, Fukuda T, Kondo Y, Ara T, Eto T, Mori Y, Matsuoka K-I, et al. HLA haploidentical stem cell transplantation from HLA homozygous donors to HLA heterozygous donors may have lower survival rates than haploidentical transplantation from HLA heterozygous donors to HLA heterozygous donors: a retrospective nationwide analys. Int J Hematol. 2024.
Sumii Y, Kondo T, Ikegawa S, Fukumi T, Iwamoto M, Nishimura MFiliz, Sugiura H, Sando Y, Nakamura M, Meguri Y, et al. Hematopoietic stem cell-derived Tregs are essential for maintaining favorable B cell lymphopoiesis following posttransplant cyclophosphamide. JCI Insight. 2023;8(8).
F
Kamijo K, Shimomura Y, Shinohara A, Mizuno S, Kanaya M, Usui Y, Kim S-W, Ara T, Mizuno I, Kuriyama T, et al. Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation. Ann Hematol. 2023.

Pages